CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893

Journal of Immunotherapy

Volumn 33, Issue 8, 2010, Pages 810-816

  Kalbasi, Anusha ^a   Fonsatti, Ester ^b   Natali, Pier Giorgio ^c   Altomonte, Maresa ^b   Bertocci, Erica ^b   Cutaia, Ornella ^b   Calabrò, Luana ^b   Chiou, Michael ^a   Tap, William ^a   Chmielowski, Bartosz ^a   Maio, Michele ^a,d   Ribas, Antoni ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c UNIVERSITY OF CHIETI   (Italy)

^d CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

CD40; immunotherapy; melanoma

Indexed keywords

CD40 ANTIGEN; CP 870893;

ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOCYTIC NEVUS; MELANOMA; METASTASIS; PRIMARY TUMOR; PRIORITY JOURNAL;

EID: 77958045597     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3181ee73a7     Document Type: Article

References (33)

1. Yang Y, Wilson JM. CD40 ligand-dependent T cell activation: requirement of B7-CD28 signaling through CD40. Science. 1996;273:1862-1864.
2. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell [see comments]. Nature. 1998;393:474-478.
3. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions [see comments]. Nature. 1998;393:480-483.
4. Bennett SR, Carbone FR, Karamalis F, et al. Help for cytotoxic-T-cell responses is mediated by CD40 signalling [see comments]. Nature. 1998;393:478-480.
5. Sotomayor EM, Borrello I, Tubb E, et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat Med. 1999;5:780-787.
6. Ribas A, Butterfield LH, Amarnani SN, et al. CD40 cross-linking bypasses the absolute requirement for CD4T cells during immunization with melanoma antigen gene-modified dendritic cells. Cancer Res. 2001;61:8787-8793.
7. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 2003;10:1-13.
8. Thomas WD, Smith MJ, Si Z, et al. Expression of the co-stimulatory molecule CD40 on melanoma cells. Int J Cancer. 1996;68:795-801.
9. Von Leoprechting A, van der Bruggen P, Pahl HL, et al. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 1999;59:1287-1294.
10. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083-1088.
11. Vonderheide RH, Flaherty KT, Khalil M, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25:876-883.
12. Altomonte M, Gloghini A, Bertola G, et al. Differential expression of cell adhesion molecules CD54/CD11a and CD58/ CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res. 1993;53:3343-3348.
13. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032. J Transl Med. 2010;8:39.
14. 0-deoxycytidine (5-AZA-CdR). J Immunother. 1999;22: 16-24.
15. Finn RS, Dering J, Conklin D, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.
16. Khan AN, Magner WJ, Tomasi TB. An epigenetically altered tumor cell vaccine. Cancer Immunol Immunother. 2004;53:748-754.
17. Khan AN, Magner WJ, Tomasi TB. An epigenetic vaccine model active in the prevention and treatment of melanoma. J Transl Med. 2007;5:64.
18. Ribas A, Hanson DC, Noe DA, et al. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer. Oncologist. 2007;12:873-883.
19. Sigalotti L, Coral S, Fratta E, et al. Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy. Semin Oncol. 2005;32:473-478.
20. Fonsatti E, Sigalotti L, Coral S, et al. Methylation-regulated expression of HLA class I antigens in melanoma. Int J Cancer. 2003;105:430-431; author reply 432-433.
21. Vo DD, Prins RM, Begley JL, et al. Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res. 2009;69:8693-8699.
22. Magner WJ, Kazim AL, Stewart C, et al. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J Immunol. 2000;165:7017-7024.
23. Maeda T, Towatari M, Kosugi H, et al. Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood. 2000;96: 3847-3856.
24. Khan AN, Gregorie CJ, Tomasi TB. Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells. Cancer Immunol Immunother. 2008;57:647-654.
25. Setiadi AF, Omilusik K, David MD, et al. Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors. Cancer Res. 2008;68:9601-9607.
26. Skov S, Pedersen MT, Andresen L, et al. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res. 2005;65:11136-11145.
27. Armeanu S, Bitzer M, Lauer UM, et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 2005;65:6321-6329.
28. Zhang XD, Gillespie SK, Borrow JM, et al. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochem Pharmacol. 2003;66:1537-1545.
29. Zhang XD, Gillespie SK, Borrow JM, et al. The histone deacetylase inhibitor suberic bishydroxamate regulates the expression of multiple apoptotic mediators and induces mitochondria-dependent apoptosis of melanoma cells. Mol Cancer Ther. 2004;3:425-435.
30. Peart MJ, Smyth GK, van Laar RK, et al. Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci \USA. 2005;102:3697-3702.
31. Insinga A, Monestiroli S, Ronzoni S, et al. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med. 2005;11:71-76.
32. Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005;11:77-84.
33. Murakami T, Sato A, Chun NA, et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol. 2008;128:1506-1516.